[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Highly effective H. pylori eradication therapies are currently used in Japan. However, eradication failures still appear in a considerable proportion of cases. In such refractory cases, several second-line eradication therapies and therapeutic efficacies have been only exceptionally studied. Our aims were to analyze the reasons and evaluate the second-line therapies when first-line eradication therapies fail. We make a strategy for second-line anti-H. pylori therapy in patients with previously failed treatment.
Ohkusa
T
T
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University.
Watanabe
M
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage; D001189:Aryl Hydrocarbon Hydroxylases; D017291:Clarithromycin / Q000008:administration & dosage; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008795:Metronidazole / Q000008:administration & dosage; D006899:Mixed Function Oxygenases / Q000235:genetics; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010349:Patient Compliance; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors; D017211:Treatment Failure
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin; D009853:Omeprazole